Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma
Danielle S. Potter(AstraZeneca (United States)), Anthony Letai(Dana-Farber Cancer Institute)
Cited by 21
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
|Cancer Cell|2019|361
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
|Nature Communications|2016|346